DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DWTX DOGWOOD THERAPEUTICS INC

交易中 06-10 10:28:32 EDT

1.43

-0.02

-1.38%

最高1.50	最低1.42	成交量1.20万
今开1.43	昨收1.45	日振幅5.69%
总市值4,809万	流通市值1,000万	总股本3,363万
成交额1.75万	换手率0.17%	流通股本699.59万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":1.43,"timestamp":1781101711643,"preClose":1.45,"halted":0,"volume":12014,"delay":0,"changeRate":-0.013793103448275874,"floatShares":6995900,"shares":33629553,"eps":-10.6022,"marketStatus":"交易中","change":-0.02,"latestTime":"06-10 10:28:32 EDT","open":1.43,"high":1.5,"low":1.4175,"amount":17485.4170814,"amplitude":0.056897,"askPrice":1.5,"askSize":182,"bidPrice":1.43,"bidSize":260,"shortable":3,"etf":0,"ttmEps":-10.6022,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781121600000},"marketStatusCode":2,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":1.45,"preHourTrading":{"tag":"盘前","latestPrice":1.4,"preClose":1.45,"latestTime":"09:25 EDT","volume":1031,"amount":1464.035465,"timestamp":1781097910001,"change":-0.05,"changeRate":-0.034483,"amplitude":0.075862},"postHourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.45,"latestTime":"16:53 EDT","volume":26,"amount":38.86,"timestamp":1781038413654,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.575642},"requestUrl":"/m/hq/s/DWTX/wiki","defaultTab":"wiki","newsList":[{"id":"1137042063","title":"Dogwood Therapeutics Inc - 扩展试验数据将支持2027年上半年三期项目向FDA提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1137042063","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137042063?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:46","pubTimestamp":1779108396,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc 宣布，其扩展试验数据将为公司在2027年上半年向美国食品药品监督管理局（FDA）提交三期项目申请提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159504779","title":"Dogwood Therapeutics 2026年第一季度净亏损500万美元，合每股0.15美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159504779","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159504779?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:35","pubTimestamp":1778762111,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc公布2026年第一季度财务业绩，归属于普通股股东的净亏损为500万美元，摊薄后每股亏损0.15美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141459489","title":"Dogwood Therapeutics 宣布达成历史抗病毒资产合作，潜在价值高达1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141459489","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141459489?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:34","pubTimestamp":1778762087,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc 宣布，已就一批历史抗病毒资产达成一项合作协议。该合作潜在价值最高可达1亿美元，标志着公司在盘活非核心资产、挖掘其潜在价值方面取得了重要进展。此次合作旨在通过外部专业力量，进一步开发这些资产的商业潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191715043","title":"Dogwood Therapeutics 达成抗病毒资产全球开发与商业化合作 潜在价值高达1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191715043","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191715043?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:01","pubTimestamp":1776949299,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC 近日宣布，已就旗下抗病毒资产达成一项全球范围内的开发与商业化战略合作伙伴关系。此次合作蕴含巨大潜力，其总价值有望攀升至1亿美元，标志着公司在抗病毒治疗领域迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176419965","title":"Dogwood Therapeutics旗下Serpin Pharma获美国国家癌症研究所250万美元资助 用于SP16一期B阶段试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1176419965","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176419965?lang=zh_cn&edition=full","pubTime":"2026-04-15 21:15","pubTimestamp":1776258902,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc旗下子公司Serpin Pharma近日宣布，已获得美国国家癌症研究所（National Cancer Institute）提供的250万美元资助。该项资金将专项用于支持SP16药物的一期B阶段临床试验（Phase 1B Trial）的推进工作。\n该资助标志着SP16在肿瘤治疗领域的研发取得重要进展。一期B阶段试验将重点评估SP16在特定患者群体中的安全性、耐受性及初步疗效，为后续临床研究奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158453332","title":"Dogwood Therapeutics与合作伙伴Serpin Pharma预计SP16药物1B期临床试验将于2026年年中启动患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1158453332","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158453332?lang=zh_cn&edition=full","pubTime":"2026-04-15 21:07","pubTimestamp":1776258439,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc及其合作伙伴Serpin Pharma近日宣布，针对SP16药物的1B期临床试验预计将于2026年中期正式启动患者招募工作。这一重要进展标志着该创新疗法在临床开发道路上迈出关键一步。\n两家公司透露，此次临床试验将重点评估SP16在特定患者群体中的安全性和有效性。该时间节点的确定基于前期研究数据的积极反馈以及监管沟通的顺利推进。研究人员表示，这一里程碑事件将为后续临床开发计划奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183833289","title":"Dogwood Therapeutics宣布FDA受理SP16研究性新药申请 用于治疗化疗引发疼痛及神经病变","url":"https://stock-news.laohu8.com/highlight/detail?id=1183833289","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183833289?lang=zh_cn&edition=full","pubTime":"2026-04-15 21:02","pubTimestamp":1776258152,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics公司宣布，美国食品药品监督管理局（FDA）已正式受理其SP16研究性新药（IND）申请。该申请旨在探索SP16用于治疗化疗引起的疼痛和神经病变的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160646340","title":"Dogwood Therapeutics宣布Halneuron®二期B阶段试验完成50%患者入组，关键数据预计2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1160646340","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160646340?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:32","pubTimestamp":1770039150,"startTime":"0","endTime":"0","summary":"生物制药公司Dogwood Therapeutics（股票代码：DWTX）近日披露，其核心候选药物Halneuron®的二期B阶段临床试验已完成半数患者入组。该试验旨在评估药物治疗特定适应症的有效性与安全性，目前进展符合预期时间表。\n公司明确表示，此次试验的关键顶线数据预计将于2026年第三季度正式对外公布。若结果达到临床终点，将为后续申报上市提供重要依据。\n市场对Halneuron®的商业潜力持续关注，该进展被视为公司研发管线推进的重要里程碑。Dogwood Therapeutics强调将严格遵循临床试验规范，确保数据收集的准确性与完整性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164963651","title":"Dogwood Therapeutics计划于2026年底向FDA提交Halneuron二期研究总结、生产计划及三期临床开发方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1164963651","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164963651?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:39","pubTimestamp":1768916372,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC宣布，公司预计在2026年年底前向美国食品药品监督管理局（FDA）提交Halneuron药物二期临床试验的总结报告。此次提交内容将全面涵盖该阶段的研究数据与分析结论。\n同时，公司还将呈报详细的生产工艺方案以及三期临床试验的整体开发规划。这一系列提交标志着Halneuron项目从中期研究向关键性临床试验阶段推进的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190589246","title":"DOGWOOD THERAPEUTICS INC 2026年展望：Halneuron推进至2B期开发阶段，最终数据预计于2026年第三季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1190589246","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190589246?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:35","pubTimestamp":1768916152,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC在2026年将继续推进其候选药物Halneuron的临床开发进程，目前该药物已进入关键的2B期临床试验阶段。公司计划稳步推进相关研究工作，最终的2B期临床试验数据预计将在2026年第三季度正式对外公布。这一重要时间节点的设定，标志着Halneuron研发项目取得了实质性进展，也为后续的临床开发路径奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603986607","title":"Dogwood Therapeutics, Inc.盘中异动 快速拉升5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986607","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986607?lang=zh_cn&edition=full","pubTime":"2026-01-15 04:43","pubTimestamp":1768423421,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日04时43分，Dogwood Therapeutics, Inc.股票出现波动，股价急速拉升5.22%。Dogwood Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。其相关个股中，Alpha Tau Medical Ltd C/Wts 、Tango Therapeutics, Inc.、Sutro Biopharma, Inc.涨幅较大，Briacell Therapeutics Corp.、Clearmind Medicine Inc.、Nrx Pharmaceuticals, Inc.较为活跃，换手率分别为277.46%、82.38%、72.64%，振幅较大的相关个股有Alpha Tau Medical Ltd C/Wts 、Briacell Therapeutics Corp C/Wts 、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为56.54%、46.51%、41.18%。Dogwood Therapeutics, Inc.公司简介：Dogwood Therapeutics Inc前身为Virios Therapeutics Inc，是一家处于开发阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115044342953ccc68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115044342953ccc68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","DWTX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186306380","title":"Dogwood Therapeutics公司获2680万美元融资 推进Halneuron®二期B阶段研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1186306380","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186306380?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:34","pubTimestamp":1768224864,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics公司近日宣布成功获得高达2680万美元的融资支持，该笔资金将专项用于推进其核心候选药物Halneuron®完成二期临床试验B阶段的研究工作。此次融资将为Halneuron®的临床开发计划提供关键资源保障，标志着该创新疗法在神经疾病治疗领域迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139","00775","BK1161","BK1569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592184118","title":"Dogwood Therapeutics, Inc.盘中异动 快速跳水5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592184118","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592184118?lang=zh_cn&edition=full","pubTime":"2025-12-19 04:07","pubTimestamp":1766088444,"startTime":"0","endTime":"0","summary":"北京时间2025年12月19日04时07分，Dogwood Therapeutics, Inc.股票出现波动，股价快速下跌5.32%。Dogwood Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.67%。其相关个股中，Protagenic Therapeutics Inc C/Wts 26/04/2026 、Athira Pharma, Inc.、Greenwich Lifesciences, Inc.涨幅较大，Athira Pharma, Inc.、Biodexa Pharmaceuticals Plc、Aditxt, Inc.较为活跃，换手率分别为1483.15%、291.20%、113.88%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 26/04/2026 、健永生技、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为65.12%、45.85%、44.39%。Dogwood Therapeutics, Inc.公司简介：Dogwood Therapeutics Inc前身为Virios Therapeutics Inc，是一家处于开发阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219040724953b6d41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219040724953b6d41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","DWTX","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113120173","title":"DOGWOOD THERAPEUTICS INC - 与Northland Securities签署股票分销协议 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1113120173","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113120173?lang=zh_cn&edition=full","pubTime":"2025-11-29 03:20","pubTimestamp":1764357619,"startTime":"0","endTime":"0","summary":"DOGWOOD THERAPEUTICS INC - 与Northland Securities签署股票分销协议 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.dwtx.com;www.dwtx.com","stockEarnings":[{"period":"1week","weight":-0.1317},{"period":"1month","weight":-0.1212},{"period":"3month","weight":-0.484},{"period":"6month","weight":-0.7741},{"period":"1year","weight":-0.7059},{"period":"ytd","weight":-0.6514}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dogwood Therapeutics, Inc.最初于2012年2月28日在阿拉巴马州成立，后来改为内华达州公司。Dogwood是一家尚未盈利的生物制药公司，处于研发阶段，专注于发现和开发治疗疼痛和神经病变的新药。公司研发管线主要集中于慢性神经性疼痛和神经病变，其核心产品是Halneuron Nav1.7调节剂项目。该项目是一种专有的非阿片类镇痛方法，通过靶向电压门控钠通道Nav1.7来减轻疼痛。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.643793},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.153661},{"month":3,"riseRate":0.5,"avgChangeRate":0.00331},{"month":4,"riseRate":0.333333,"avgChangeRate":0.090085},{"month":5,"riseRate":0.5,"avgChangeRate":0.166607},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.039276},{"month":7,"riseRate":0.6,"avgChangeRate":0.194525},{"month":8,"riseRate":0.4,"avgChangeRate":-0.123213},{"month":9,"riseRate":0.4,"avgChangeRate":-0.126251},{"month":10,"riseRate":0.2,"avgChangeRate":-0.193945},{"month":11,"riseRate":0.8,"avgChangeRate":-0.028445},{"month":12,"riseRate":0.4,"avgChangeRate":-0.112321}],"exchange":"NASDAQ","name":"DOGWOOD THERAPEUTICS INC","nameEN":"DOGWOOD THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供DOGWOOD THERAPEUTICS INC(DWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"DOGWOOD THERAPEUTICS INC,DWTX,DOGWOOD THERAPEUTICS INC股票,DOGWOOD THERAPEUTICS INC股票老虎,DOGWOOD THERAPEUTICS INC股票老虎国际,DOGWOOD THERAPEUTICS INC行情,DOGWOOD THERAPEUTICS INC股票行情,DOGWOOD THERAPEUTICS INC股价,DOGWOOD THERAPEUTICS INC股市,DOGWOOD THERAPEUTICS INC股票价格,DOGWOOD THERAPEUTICS INC股票交易,DOGWOOD THERAPEUTICS INC股票购买,DOGWOOD THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DOGWOOD THERAPEUTICS INC(DWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供DOGWOOD THERAPEUTICS INC(DWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}